help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newman, C. B.
Right arrow Articles by Gagel, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newman, C. B.
Right arrow Articles by Gagel, R. F.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 2768-2775, Copyright © 1995 by Endocrine Society

ARTICLES

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study [published erratum appears in J Clin Endocrinol Metab 1995 Nov;80(11):3238]

CB Newman, S Melmed, PJ Snyder, WF Young, LD Boyajy, R Levy, WN Stewart, A Klibanski, ME Molitch and RF Gagel
Department of Medicine, New York University Medical Center, New York, USA.

One hundred and three acromegalic patients from 14 medical centers were enrolled in this study to determine the efficacy and safety of the somatostatin analog, octreotide acetate, during long term treatment. Seventy percent of the patients had undergone previous surgery or radiation treatment. Octreotide was initiated at a dose of 100 micrograms, sc, every 8 h and gradually increased to a maximum of 1500 micrograms daily depending upon the individual patient's clinical and biochemical response [GH and insulin-like growth factor I (IGF-I) reduction]. The mean duration of treatment was 24 months (range, 3-30 months). However, most patients were treated for a mean of 30 months, because this study took place after an initial 6-month study previously reported. Mean serum GH fell from 30.9 micrograms/L (range, 2.7-350) to 5.7 micrograms/L (range, 0.6-59) at the 3 months visit and remained suppressed (P < 0.001). Plasma IGF-I concentrations were also significantly reduced and remained in the normal range for at least half of the treatment visits in 56 of 87 patients (64%) treated for 12- 30 months. Patients with higher initial GH concentrations were less likely to normalize IGF-I concentrations during treatment (P < 0.001). There was no evidence of drug tachyphylaxis in those patients who continued taking stable doses of medication. With some exceptions, dose increments above 800 micrograms daily in 31 patients did not provide additional benefit in terms of GH and IGF-I reduction. Headache, excessive perspiration, fatigue, and joint pain were ameliorated in 83- 95% of patients. Mean finger circumference was decreased significantly at the 12 month visit (P < 0.05). The most common adverse events reported were diarrhea, abdominal discomfort, loose stools, and nausea; these symptoms usually disappeared within 3 months of treatment. Five patients discontinued octreotide because of adverse events. Of 102 patients with normal baseline ultrasound examinations of the gallbladder, 24 patients (23.5%) developed gallstones (usually during the first year of treatment), and 21 patients developed sludge alone. Gallstone formation was not related to the dose of octreotide. Most patients with cholelithiasis were asymptomatic, and none developed cholecystitis. These observations suggest that octreotide is a valuable long term medical treatment for acromegaly.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
R. Lindberg-Larsen, N. Moller, O. Schmitz, S. Nielsen, M. Andersen, H. Orskov, and J. O. L. Jorgensen
The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1724 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Fedele, I. De Martino, R. Pivonello, A. Ciarmiello, M. L. Del Basso De Caro, R. Visone, D. Palmieri, G. M. Pierantoni, C. Arra, H. A. Schmid, et al.
SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas
Clin. Cancer Res., May 1, 2007; 13(9): 2738 - 2744.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio, S. Lodrini, P. Doneda, L. Cortesi, and G. Pagani
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1397 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
W. Ruan, F. Fahlbusch, D. R. Clemmons, M. E. Monaco, P. D. Walden, A. P. Silva, H. A. Schmid, and D. L. Kleinberg
SOM230 Inhibits Insulin-Like Growth Factor-I Action in Mammary Gland Development by Pituitary Independent Mechanism: Mediated through Somatostatin Subtype Receptor 3?
Mol. Endocrinol., February 1, 2006; 20(2): 426 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
R. Fahlbusch, B. v Keller, O. Ganslandt, J. Kreutzer, and C. Nimsky
Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging
Eur. J. Endocrinol., August 1, 2005; 153(2): 239 - 248.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Castinetti, D. Taieb, J.-M. Kuhn, P. Chanson, M. Tamura, P. Jaquet, B. Conte-Devolx, J. Regis, H. Dufour, and T. Brue
Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4483 - 4488.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
W. W de Herder, H R. Taal, P. Uitterlinden, R. A Feelders, J. A M J L Janssen, and A.-J. van der Lely
Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly
Eur. J. Endocrinol., July 1, 2005; 153(1): 67 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. P Silva, K. Bethmann, F. Raulf, and H. A Schmid
Regulation of ghrelin secretion by somatostatin analogs in rats
Eur. J. Endocrinol., June 1, 2005; 152(6): 887 - 894.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
P. Nomikos, M. Buchfelder, and R. Fahlbusch
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
Eur. J. Endocrinol., March 1, 2005; 152(3): 379 - 387.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
N D Stafford, L T Condon, M J C Rogers, L Helboe, D A Crooks, and S L Atkin
The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas
J. Clin. Pathol., February 1, 2004; 57(2): 168 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. R. Biermasz, A. M. Pereira, M. Frolich, J. A. Romijn, J. D. Veldhuis, and F. Roelfsema
Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E25 - E30.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. R. Clemmons, K. Chihara, P. U. Freda, K. K. Y. Ho, A. Klibanski, S. Melmed, S. M. Shalet, C. J. Strasburger, P. J. Trainer, and M. O. Thorner
Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4759 - 4767.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Cozzi, R. Attanasio, M. Montini, G. Pagani, G. Lasio, S. Lodrini, M. Barausse, M. Albizzi, D. Dallabonzana, and A. M. Pedroncelli
Four-Year Treatment with Octreotide-Long-Acting Repeatable in 110 Acromegalic Patients: Predictive Value of Short-Term Results?
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3090 - 3098.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Saveanu, E. Lavaque, G. Gunz, A. Barlier, S. Kim, J. E. Taylor, M. D. Culler, A. Enjalbert, and P. Jaquet
Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5545 - 5552.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. J. Kopchick, C. Parkinson, E. C. Stevens, and P. J. Trainer
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
Endocr. Rev., October 1, 2002; 23(5): 623 - 646.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Weckbecker, U. Briner, I. Lewis, and C. Bruns
SOM230: A New Somatostatin Peptidomimetic with Potent Inhibitory Effects on the Growth Hormone/Insulin-Like Growth Factor-I Axis in Rats, Primates, and Dogs
Endocrinology, October 1, 2002; 143(10): 4123 - 4130.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Melmed, F. F. Casanueva, F. Cavagnini, P. Chanson, L. Frohman, A. Grossman, K. Ho, D. Kleinberg, S. Lamberts, E. Laws, et al.
Guidelines for Acromegaly Management
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4054 - 4058.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Parkinson, W. M. Drake, M. E. Roberts, K. Meeran, G. M. Besser, and P. J. Trainer
A Comparison of the Effects of Pegvisomant and Octreotide on Glucose, Insulin, Gastrin, Cholecystokinin, and Pancreatic Polypeptide Responses to Oral Glucose and a Standard Mixed Meal
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1797 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Ph. Caron, A. Beckers, D. R. Cullen, M. I. Goth, B. Gutt, P. Laurberg, A. M. Pico, M. Valimaki, and W. Zgliczynski
Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 99 - 104.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M J Veysey, P Malcolm, A I Mallet, P J Jenkins, G M Besser, G M Murphy, and R H Dowling
Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial
Gut, December 1, 2001; 49(6): 828 - 834.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. J. van der Lely, A. F. Muller, J. A. Janssen, R. J. Davis, K. A. Zib, J. A. Scarlett, and S. W. Lamberts
Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 478 - 481.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Saveanu, G. Gunz, H. Dufour, P. Caron, F. Fina, L. Ouafik, M. D. Culler, J. P. Moreau, A. Enjalbert, and P. Jaquet
BIM-23244, a Somatostatin Receptor Subtype 2- and 5-Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-Resistant Human GH-Secreting Adenomas
J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 140 - 145.
[Abstract] [Full Text]

Home page
 NEJMHome page
P. J. Trainer, W. M. Drake, L. Katznelson, P. U. Freda, V. Herman-Bonert, A.J. van der Lely, E. V. Dimaraki, P. M. Stewart, K. E. Friend, M. L. Vance, et al.
Treatment of Acromegaly with the Growth Hormone-Receptor Antagonist Pegvisomant
N. Engl. J. Med., April 20, 2000; 342(16): 1171 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Jaquet, A. Saveanu, G. Gunz, F. Fina, A. J. Zamora, M. Grino, M. D. Culler, J. P. Moreau, A. Enjalbert, and L'H. Ouafik
Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral Phenotypes
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 781 - 792.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. DRANGE, N. R. FRAM, V. HERMAN-BONERT, and S. MELMED
Pituitary Tumor Registry: A Novel Clinical Resource
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 168 - 174.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
Pituitary Tumors in Children and Adolescents
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4317 - 4323.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. U. Freda and S. L. Wardlaw
Diagnosis and Treatment of Pituitary Tumors
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866.
[Full Text]

Home page
 GutHome page
M J Veysey, L A Thomas, A I Mallet, P J Jenkins, G M Besser, J A H Wass, G M Murphy, and R H Dowling
Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones
Gut, May 1, 1999; 44(5): 675 - 681.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
C. W. Ko, J. H. Sekijima, and S. P. Lee
Biliary Sludge
Ann Intern Med, February 16, 1999; 130(4_Part_1): 301 - 311.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
J. S. Fuqua and G. D. Berkovitz
Growth Hormone Excess in a Child with Neurofibromatosis Type 1 and Optic Pathway Tunor: A Patient Report
Clinical Pediatrics, December 1, 1998; 37(12): 749 - 752.
[PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Melmed
Tight Control of Growth Hormone: An Attainable Outcome for Acromegaly Treatment
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3409 - 3410.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. U. Freda and S. L. Wardlaw
Editorial: Primary Medical Therapy for Acromegaly
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3031 - 3033.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. B. Newman, S. Melmed, A. George, D. Torigian, M. Duhaney, P. Snyder, W. Young, A. Klibanski, M. E. Molitch, R. Gagel, et al.
Octreotide as Primary Therapy for Acromegaly
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3034 - 3040.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Drange and S. Melmed
Long-Acting Lanreotide Induces Clinical and Biochemical Remission of Acromegaly Caused by Disseminated Growth Hormone-Releasing Hormone-Secreting Carcinoid
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3104 - 3109.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Melmed, I. Jackson, D. Kleinberg, and A. Klibanski
Current Treatment Guidelines for Acromegaly
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2646 - 2652.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. L. Barkan, I. Halasz, K. J. Dornfeld, C. A. Jaffe, R. D. Friberg, W. F. Chandler, and H. M. Sandler
Pituitary Irradiation Is Ineffective in Normalizing Plasma Insulin-Like Growth Factor I in Patients with Acromegaly
J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3187 - 3191.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Caron, I. Morange-Ramos, M. Cogne, and P. Jaquet
Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 18 - 22.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
OCTREOTIDE FOR ACROMEGALY
Journal Watch (General), September 29, 1995; 1995(929): 8 - 8.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society